Pharmacological characterisation of JNJ-78911118, a novel, centrally-penetrant, selective GluN2A antagonist.
British Journal of Pharmacology May 13, 2025 Brian Lord, Sirak Simavorian, Ian Fraser et al. 2 citations
Non-selective NMDA receptor antagonism produces rapid symptom improvement in treatment-resistant depression; however, associated side effects necessitate medical oversight during administration. We hypothesised that selective GluN2A antagonism could provide similar efficacy with an improved side effect profile. Here, we report the pharmacology of JNJ-78911118, a brain-penetrant, GluN2A...